latest report, PI3K Signaling Pathway Analysis: A Shifting Marketed and Pipeline Product Landscape, as Blockbusters Expire and Development Moves Towards Downstream Targets, provides a comprehensive assessment of the marketed and pipeline products acting on various components of the phosphoinositide 3-kinase (PI3K) signaling network.
The PI3K pathway is a critical signal transduction pathway and plays important roles in the regulation of many cellular processes including protein synthesis, cell-cycle progression and cell survival. Additionally, numerous diseases are known to be associated with dysregulated PI3K signaling. Consequently, the PI3K signaling pathway has been extensively researched over recent decades and is widely recognized as a prime target for therapeutic intervention. Indeed, globally, 2,129 products that target components of the PI3K signaling network have gained market approval to date.
These include a number of highly clinically and commercially successful therapies such as the blockbuster drugs Herceptin (trastuzumab), Avastin (bevacizumab) and Lantus (insulin glargine). Despite this, PI3K signaling remains a focal point of drug discovery as many components of the pathway are yet to be targeted by currently available pharmaceuticals. There are 2,067 pipeline products in development that target components of the PI3K pathway, many of which act on first-in-class molecular targets.
The following report discusses the significance of the PI3K pathway, including its role in disease, and provides a comprehensive overview of the PI3K marketed and pipeline landscapes. The report provides a breakdown of the following key signaling pathways within the PI3K network in terms of marketed and pipeline activity: PI3K/AKT/mTOR pathway, Ras/Raf/MEK/ERK pathway, cell survival pathways downstream of AKT, cell-cycle progression pathways downstream of AKT, metabolism pathways downstream of AKT and kinases downstream of PDK1.
An analysis of the marketed and pipeline activity across various nodes (defined as groups of molecules which have the same role in response to a stimulus) within each of these pathways is provided. An examination of the marketed and pipeline products acting on each of these pathways in terms of molecule type and therapy area, and, in the case of pipeline products, novelty and stage of development, provides further granularity. Additionally, detailed product profiles of key marketed products are provided, which incorporate clinical and commercial perspectives and include historical and forecast annual sales revenues. The report concludes with a discussion of promising late-stage pipeline products.
- Which products that target components of the PI3K network are most commercially successful and which indications are these products approved for?
- What is the range of molecule types that act on components of the PI3K network?
- Which nodes across the various pathways are not currently targeted by marketed products and how many pipeline products act on these nodes?
- What is the distribution of pipeline products by stage of development across various nodes?
- Which late-stage pipeline products are projected to be the most commercially successful?
Reasons to buy
- Appreciate the significance and complexity of the PI3K signaling network, with visual schematics of the overall network, as well as breakdowns of the key signaling pathways, by node.
- Understand the current status of the PI3K marketed landscape, and the relative clinical and commercial success of currently marketed products.
- Analyze the PI3K pipeline landscape and gain insight into the pipeline products that act on novel molecular targets within the PI3K network.
Frequently Asked Questions
- By product type
- By End User/Applications
- By Technology
- By Region